Human Genome Epidemiology Literature Finder
|
Records 1 - 16 (of 16 Records) |
| Query Trace: Nausea and BRCA2[original query] |
|---|
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (London, England) 2010 Jul 376 (9737): 245-51. Audeh M William, Carmichael James, Penson Richard T, Friedlander Michael, Powell Bethan, Bell-McGuinn Katherine M, Scott Clare, Weitzel Jeffrey N, Oaknin Ana, Loman Niklas, Lu Karen, Schmutzler Rita K, Matulonis Ursula, Wickens Mark, Tutt Andr |
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (London, England) 2010 Jul 376 (9737): 235-44. Tutt Andrew, Robson Mark, Garber Judy E, Domchek Susan M, Audeh M William, Weitzel Jeffrey N, Friedlander Michael, Arun Banu, Loman Niklas, Schmutzler Rita K, Wardley Andrew, Mitchell Gillian, Earl Helena, Wickens Mark, Carmichael Jam |
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet. Oncology 2011 Sep 12 (9): 852-61. Gelmon Karen A, Tischkowitz Marc, Mackay Helen, Swenerton Kenneth, Robidoux André, Tonkin Katia, Hirte Hal, Huntsman David, Clemons Mark, Gilks Blake, Yerushalmi Rinat, Macpherson Euan, Carmichael James, Oza Am |
| The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. The Lancet. Oncology 2015 Jan 16 (1): 87-97. Oza Amit M, Cibula David, Benzaquen Ana Oaknin, Poole Christopher, Mathijssen Ron H J, Sonke Gabe S, Colombo Nicoletta, Špa?ek Ji?í, Vuylsteke Peter, Hirte Holger, Mahner Sven, Plante Marie, Schmalfeldt Barbara, Mackay Helen, Rowbottom Jacqui, Lowe Elizabeth S, Dougherty Brian, Barrett J Carl, Friedlander Micha |
| A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet. Oncology 2016 Sep . Ledermann Jonathan A, Harter Philipp, Gourley Charlie, Friedlander Michael, Vergote Ignace, Rustin Gordon, Scott Clare, Meier Werner, Shapira-Frommer Ronnie, Safra Tamar, Matei Daniela, Fielding Anitra, Spencer Stuart, Rowe Philip, Lowe Elizabeth, Hodgson Darren, Sovak Mika A, Matulonis Ursu |
| Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecologic oncology 2017 9 147 (2): 267-275. Oza Amit M, Tinker Anna V, Oaknin Ana, Shapira-Frommer Ronnie, McNeish Iain A, Swisher Elizabeth M, Ray-Coquard Isabelle, Bell-McGuinn Katherine, Coleman Robert L, O'Malley David M, Leary Alexandra, Chen Lee-May, Provencher Diane, Ma Ling, Brenton James D, Konecny Gottfried E, Castro Cesar M, Giordano Heidi, Maloney Lara, Goble Sandra, Lin Kevin K, Sun James, Raponi Mitch, Rolfe Lindsey, Kristeleit Rebecca |
| Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European journal of cancer (Oxford, England : 1990) 2017 12 89 19-26. Lowery Maeve A, Kelsen David P, Capanu Marinela, Smith Sloane C, Lee Jonathan W, Stadler Zsofia K, Moore Malcolm J, Kindler Hedy L, Golan Talia, Segal Amiel, Maynard Hannah, Hollywood Ellen, Moynahan MaryEllen, Salo-Mullen Erin E, Do Richard Kinh Gian, Chen Alice P, Yu Kenneth H, Tang Laura H, O'Reilly Eileen |
| Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 9 36 (31): 3134-3143. Cruz Cristina, Llop-Guevara Alba, Garber Judy E, Arun Banu K, Pérez Fidalgo José A, Lluch Ana, Telli Melinda L, Fernández Cristian, Kahatt Carmen, Galmarini Carlos M, Soto-Matos Arturo, Alfaro Vicente, Pérez de la Haza Aitor, Domchek Susan M, Antolin Silvia, Vahdat Linda, Tung Nadine M, Lopez Rafael, Arribas Joaquín, Vivancos Ana, Baselga José, Serra Violeta, Balmaña Judith, Isakoff Steven |
| A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical cancer research : an official journal of the American Association for Cancer Research 2018 12 25 (9): 2717-2724. Turner Nicholas C, Telli Melinda L, Rugo Hope S, Mailliez Audrey, Ettl Johannes, Grischke Eva-Maria, Mina Lida A, Balmaña Judith, Fasching Peter A, Hurvitz Sara A, Wardley Andrew M, Chappey Colombe, Hannah Alison L, Robson Mark E, |
| A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Investigational new drugs 2018 1 36 (5): 828-835. van der Biessen Diane A J, Gietema Jourik A, de Jonge Maja J A, Desar Ingrid M E, den Hollander Martha W, Dudley Matthew, Dunbar Martin, Hetman Robert, Serpenti Camille, Xiong Hao, Mittapalli Rajendar K, Timms Kirsten M, Ansell Peter, Ratajczak Christine K, Shepherd Stacie Peacock, van Herpen Carla M |
| Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. The breast journal 2020 6 26 (8): 1572-1582. Bayraktar Soley, Zhou Jade Z, Bassett Roland, Gutierrez Barrera Angelica M, Layman Rachel M, Valero Vicente, Arun Ba |
| Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study. ESMO open 2022 8 7 (5): 100571. Boni V, Pistilli B, Braña I, Shapiro G I, Trigo J, Moreno V, Castellano D, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Longo F, Zaman K, Antón A, Paredes A, Huidobro G, Subbiah |
| Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib. Biomedicines 2022 11 10 (11): . Botrus Gehan, Roe Denise, Jameson Gayle S, Junior Pedro Luiz Serrano Uson, Korn Ronald Lee, Caldwell Lana, Bargenquast Taylor, Miller Max, Borazanci Erkut Has |
| Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecologic oncology 2022 1 164 (3): 498-504. Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez M J Rubio, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof |
- Page last reviewed:Feb 1, 2024
- Content source: